RxDoctor Payments Data

Deric Savior, MD

Medical Oncology · Wynnewood, PANPI 1912183765

Payments from drug & device makers

$394,667in general payments, 2019–2025

Across 895 payments — averaging $440.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$123K
  • Sanofi$68K
  • Jazz Pharmaceuticals Inc.$68K
  • Janssen Research & Development, LLC$51K
  • Johnson & Johnson$25K
  • Bristol Myers Squibb$16K
  • plus $44K from 54 others

What the payments were for

  • Consulting fees$65,02819%
  • Speaking & faculty fees$223,44665%
  • Travel & lodging$29,0118%
  • Food & beverage$25,4707%
  • Education$3620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron Healthcare Solutions, Inc.120$122,762
Sanofi65$68,206
Jazz Pharmaceuticals Inc.86$67,988
Janssen Research & Development, LLC3$51,350
Johnson & Johnson52$24,578
Bristol Myers Squibb29$15,727
E.r. Squibb & Sons, L.L.C.27$5,599
Boehringer Ingelheim6$5,406
Regeneron5$3,987
Fosun Pharma USA Inc.2$3,820
AstraZeneca(2 entities)64$3,661
Eli Lilly2$2,925
EMD Serono, Inc.6$2,220
Blueprint Medicines Corporation6$2,123
Bayer14$1,978
Takeda Pharmaceuticals U.S.A., Inc.12$1,967
Novartis46$991
Astellas Pharma US Inc25$758
Merck18$711
Lilly USA, LLC12$581
Seagen Inc.13$541
Genentech USA, Inc.20$460
Eisai Inc.20$456
Gilead(2 entities)15$450
Incyte Corporation21$405
GSK18$374
Daiichi Sankyo Inc.15$364
Pfizer14$269
Boston Scientific2$248
Dendreon Pharmaceuticals LLC2$224
Caris MPI, Inc.4$204
Ipsen Biopharmaceuticals, Inc8$199
AbbVie9$191
Exelixis Inc.5$176
Tempus AI, Inc8$171
Genmab U.S., Inc.6$139
Array Biopharma Inc6$122
Beigene USA, Inc.5$120
Beone Medicines USA, Inc.5$117
Sobi, Inc6$115
Pharmacosmos Therapeutics Inc.6$110
Acrotech Biopharma Inc.5$108
Tersera Therapeutics LLC5$100
Taiho Oncology, Inc.4$95
Pharmaessentia USA Corporation4$93
Puma Biotechnology, Inc.5$93
Karyopharm Therapeutics Inc.3$90
Amgen5$90
Stemline Therapeutics Inc.4$86
Mirati Therapeutics, Inc.4$79
Morphosys, US Inc.4$75
Sanofi-aventis U.S. LLC1$70
Novocure Inc.3$66
AVEO Pharmaceuticals, Inc.3$64
Immunogen, Inc.2$60
Legend Biotech USA Inc.2$55
Rigel Pharmaceuticals, Inc.3$54
Deciphera Pharmaceuticals Inc.3$51
Sumitomo Pharma America, Inc.3$51
Apellis Pharmaceuticals, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394,667 in reported general payments places this provider in the 70th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,058,043
Medicare patients
164
Services billed
64,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate26$442,143
MekinistTrametinib Dimethyl Sulfoxide11$176,261
Prochlorperazine Maleate23$391
Ondansetron Hcl17$373
Sodium Chloride0.9 % Sodium Chloride15$215
Venlafaxine Hcl ErVenlafaxine Hcl14$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$3,661$442,14326 claims
NovartisMekinist$991$176,26111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 238 medical oncology providers in Pennsylvania.

Other medical oncology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →